Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.

I n a world where seeking help to manage weight is still frowned upon and deemed as “lazy,” many are turning to common tools ...

Novo Nordisk’s once‐weekly injectable, Ozempic (semaglutide), originally developed for type 2 diabetes, has increasingly ...

Cinnamon tea is a source of antioxidants and may bring various health benefits. Learn how to make it and possible side ...

A novel islet cell therapy delivered through a single infusion lowered HbA1c and eliminated severe hypoglycemia events for ...

The drug has been approved to help treat type-2 diabetes, but a new study shows an increase in use in people with type-2 diabetes- and it may not be safe.

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

There’s no question about the popularity of GLP-1 weight loss drugs like Ozempic and Wegovy, but some doctors are worried the ...

Five abstracts showcase critical insights into women’s cardiovascular health, highlighting rising maternal mortality, ...

Gallagher Re, a reinsurance brokerage and risk management services provider, has released a report on the impact of GLP-1 ...

A new study adds to evidence to suggest the main ingredient in Novo Nordisk’s injectable drug for type 2 diabetes may ...